Literature DB >> 9294837

Hepatitis B virus DNA in serum and blood cells of hepatitis B surface antigen-negative hemodialysis patients and staff.

M Cabrerizo1, J Bartolomé, P De Sequera, C Caramelo, V Carreño.   

Abstract

Patients undergoing chronic hemodialysis, as well as dialysis staff members, are at high risk of infection with hepatitis B virus (HBV). We have analyzed by PCR the presence of HBV DNA in serum and peripheral blood mononuclear cells (PBMC) from 33 hepatitis B surface antigen (HBsAg)-negative hemodialysis patients and 24 dialysis unit staff members; eight of the 24 staff members had an acute hepatitis B resolved 13 to 21 yr before. HBV DNA was detected in serum of 19 (58%) patients (12 of 17 with and 7 of 16 without anti-HBV antibodies). HBV DNA was found in PBMC of 18 (54%) patients (13 of 17 with and 5 of 16 without anti-HBV antibodies). In the staff members, serum HBV DNA was found only in the individuals who suffered a previous acute hepatitis (P < 0.005). HBV DNA was detected in PBMC of four of six staff members (all with previous acute hepatitis). In two HBV DNA-positive PBMC samples, viral RNA was detected by reverse transcription-PCR. To ascertain whether the HBV DNA detected in serum was encapsulated, seven HBV DNA-positive serum samples were digested with DNase before PCR. After treatment, HBV DNA remained detectable in four cases. In conclusion, HBV DNA in serum and PBMC is detectable in a high proportion of HBsAg-negative hemodialysis patients and may persist several years after a resolved acute hepatitis B. The viral DNA is encapsulated and remains transcriptionally active in PBMC. In the anti-HBs-negative patients, HBV DNA is, at the present time, the only means for diagnosing a past HBV hepatitis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9294837     DOI: 10.1681/ASN.V891443

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  11 in total

Review 1.  Occult hepatitis B virus infection in Egypt.

Authors:  Ashraf Elbahrawy; Alshimaa Alaboudy; Walid El Moghazy; Ahmed Elwassief; Ahmed Alashker; Abdallah Mahmoud Abdallah
Journal:  World J Hepatol       Date:  2015-06-28

2.  HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines.

Authors:  J F Schlaak; G Tully; H F Löhr; G Gerken; K H Meyer zum Büschenfelde
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

3.  Hepatitis B virus surface antigen (HBsAg) mutants in Singapore adults and vaccinated children with high anti-hepatitis B virus antibody levels but negative for HBsAg.

Authors:  W N Chen; C J Oon
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

4.  Epidemiology of occult hepatitis B infection among thalassemic, hemophilia, and hemodialysis patients.

Authors:  Mohammad Kazemi Arababadi; Behzad Nasiri Ahmadabadi; Hassan Yousefi Daredor; Derek Kennedy
Journal:  Hepat Mon       Date:  2012-05-30       Impact factor: 0.660

5.  Seroprevalence of hepatitis B virus among hemodialysis patients in Bushehr province, southern Iran: HBV seroprevalence in hemodialysis patients.

Authors:  Amir Ahmad Mostaghni; Alireza Soltanian; Elaheh Mokhtari; Sara Japoni; Davood Mehrabani
Journal:  Hepat Mon       Date:  2011-03       Impact factor: 0.660

6.  Discrepancy between serological and virological analysis of viral hepatitis in hemodialysis patients.

Authors:  Jer-Ming Chang; Chung-Feng Huang; Szu-Chia Chen; Chia-Yen Dai; Ming-Lun Yeh; Jee-Fu Huang; Hsing-Tao Kuo; Wan-Long Chuang; Ming-Lung Yu; Shang-Jyh Hwang; Hung-Chun Chen
Journal:  Int J Med Sci       Date:  2014-03-08       Impact factor: 3.738

7.  Association of the interleukin-12 polymorphic variants with the development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients in response to vaccination or infection.

Authors:  Alicja E Grzegorzewska; Piotr M Wobszal; Anna Sowińska; Adrianna Mostowska; Paweł P Jagodziński
Journal:  Mol Biol Rep       Date:  2013-10-25       Impact factor: 2.316

Review 8.  Occult HBV infection: a faceless enemy in liver cancer development.

Authors:  Jaime Morales-Romero; Gustavo Vargas; Rebeca García-Román
Journal:  Viruses       Date:  2014-04-08       Impact factor: 5.048

Review 9.  Update on occult hepatitis B virus infection.

Authors:  Manoochehr Makvandi
Journal:  World J Gastroenterol       Date:  2016-10-21       Impact factor: 5.742

10.  Late HBsAg seroreversion of mutated hepatitis B virus after bone marrow transplantation.

Authors:  Axel Schubert; Detlef Michel; Thomas Mertens
Journal:  BMC Infect Dis       Date:  2013-05-16       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.